294 related articles for article (PubMed ID: 33333139)
1. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
2. Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Acta Oncol; 2021 Apr; 60(4):505-512. PubMed ID: 33491521
[TBL] [Abstract][Full Text] [Related]
3. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.
Liu H; Zhang X; Vinogradskiy YY; Swisher SG; Komaki R; Chang JY
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1017-23. PubMed ID: 22543216
[TBL] [Abstract][Full Text] [Related]
4. Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).
Chaudhuri AA; Binkley MS; Rigdon J; Carter JN; Aggarwal S; Dudley SA; Qian Y; Kumar KA; Hara WY; Gensheimer M; Nair VS; Maxim PG; Shultz DB; Bush K; Trakul N; Le QT; Diehn M; Loo BW; Guo HH
Radiother Oncol; 2016 Jun; 119(3):454-60. PubMed ID: 27267049
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumours: clinical usefulness of the planning target volume to total lung volume ratio.
Ueyama T; Arimura T; Takumi K; Nakamura F; Higashi R; Ito S; Fukukura Y; Umanodan T; Nakajo M; Koriyama C; Yoshiura T
Br J Radiol; 2018 Jun; 91(1086):20170453. PubMed ID: 29565649
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
7. Technical Note: Dosimetric evaluation of Monte Carlo algorithm in iPlan for stereotactic ablative body radiotherapy (SABR) for lung cancer patients using RTOG 0813 parameters.
Pokhrel D; Badkul R; Jiang H; Kumar P; Wang F
J Appl Clin Med Phys; 2015 Jan; 16(1):5058. PubMed ID: 25679161
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
[TBL] [Abstract][Full Text] [Related]
9. Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy.
Ryckman JM; Baine M; Carmicheal J; Osayande F; Sleightholm R; Samson K; Zheng D; Zhen W; Lin C; Zhang C
Radiat Oncol; 2020 Feb; 15(1):33. PubMed ID: 32054487
[TBL] [Abstract][Full Text] [Related]
10. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.
Baker R; Han G; Sarangkasiri S; DeMarco M; Turke C; Stevens CW; Dilling TJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):190-5. PubMed ID: 22929858
[TBL] [Abstract][Full Text] [Related]
11. Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.
Matsuo Y; Shibuya K; Nakamura M; Narabayashi M; Sakanaka K; Ueki N; Miyagi K; Norihisa Y; Mizowaki T; Nagata Y; Hiraoka M
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e545-9. PubMed ID: 22436782
[TBL] [Abstract][Full Text] [Related]
12. Excluding PTV from lung volume may better predict radiation pneumonitis for intensity modulated radiation therapy in lung cancer patients.
Meng Y; Yang H; Wang W; Tang X; Jiang C; Shen Y; Luo W
Radiat Oncol; 2019 Jan; 14(1):7. PubMed ID: 30642354
[TBL] [Abstract][Full Text] [Related]
13. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
Barriger RB; Forquer JA; Brabham JG; Andolino DL; Shapiro RH; Henderson MA; Johnstone PA; Fakiris AJ
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):457-62. PubMed ID: 21035956
[TBL] [Abstract][Full Text] [Related]
14. Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicity.
Murray L; Karakaya E; Hinsley S; Naisbitt M; Lilley J; Snee M; Clarke K; Musunuru HB; Ramasamy S; Turner R; Franks K
Br J Radiol; 2016; 89(1058):20150628. PubMed ID: 26760508
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy.
Harder EM; Park HS; Chen ZJ; Decker RH
Pract Radiat Oncol; 2016; 6(6):e353-e359. PubMed ID: 27156424
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy.
Kim K; Lee J; Cho Y; Chung SY; Lee JJB; Lee CG; Cho J
Radiat Oncol J; 2017 Jun; 35(2):163-171. PubMed ID: 28712275
[TBL] [Abstract][Full Text] [Related]
17. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
[TBL] [Abstract][Full Text] [Related]
18. Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy.
Yu JH; Wang CL; Liu Y; Wang JM; Lv CX; Liu J; Zhang Q; Fu XL; Cai XW
Cancer Radiother; 2021 Jun; 25(4):323-329. PubMed ID: 33446419
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of functionally weighted dose-volume parameters for thoracic stereotactic ablative radiotherapy (SABR) using CT ventilation.
Kanai T; Kadoya N; Nakajima Y; Miyasaka Y; Ieko Y; Kajikawa T; Ito K; Yamamoto T; Dobashi S; Takeda K; Nemoto K; Jingu K
Phys Med; 2018 May; 49():47-51. PubMed ID: 29866342
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and lung toxicities after lung SABR using dynamic conformal arc therapy: a single-institution cohort study.
Mesny E; Ayadi M; Dupuis P; Beldjoudi G; Tanguy R; Martel-Lafay I
Radiat Oncol; 2023 Feb; 18(1):36. PubMed ID: 36814265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
